Rejuvenation Technologies, a Mountain View, CA-based biotechnology company developing mRNA-based therapeutics to address mechanisms of aging, raised $10.6M in Seed funding.
The round, which brought the total amount raised to date to $15.2M, was led by Khosla Ventures. Shanda Ventures, Asymmetry Ventures, Merchant Adventures, Longevity Tech Fund, and Y Combinator also participated.
The company intends to use the funds to advance its programs to IND approval in fibrotic disease, such as pulmonary fibrosis and liver cirrhosis, as well as early research targeting the immune system and bring on additional team members to oversee scale-up manufacturing, clinical operations, and R&D efforts to expand mRNA delivery capabilities to additional organ systems.
Founded by John Ramunas, Ph.D., CEO, and Glenn Markov, Ph.D., COO, Rejuvenation Technologies is a biotechnology company developing mRNA therapies preventing and treating chronic age-related diseases. They start with a pipeline of therapies that target fatal diseases, including of the liver and lung. Co-founders developed fundamental technology at Stanford University in the lab of Helen Blau, who is also a co-founder, on telomere extension and epigenetic reprogramming, and innovated further at Rejuvenation.
Dan Chambers, thoracic transplant physician and lung fibrosis disease expert from The University of Queensland, will join the company as Chief Medical Officer.
FinSMEs
06/09/2023